Episode Details

Co-Diagnostics reports Q1 2026 earnings: Revenue surges to $146K from $50K last year, but net loss at $9.1M due to R&D spending. CEO Dwight Egan highlights progress towards commercialization, focusing on PCR platform for point-of-care diagnostics. Upper respiratory multiplex test enrollment completed with 1,400 patients, preparing for FDA submission in Q3 for CLIA-waived use. Indias CoSara joint venture secures manufacturing license, expanding into $13B South Asia market. Saudi Arabias CoMira venture advances, securing land for local manufacturing and tech upgrades. Cash at $8.2M, with plans for more funding as they eye U.S. TB apps in nursing homes. Analysts buzz about scalability, with manufacturing ramps ready in Utah, India, and Saudi to hit big markets affordably.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/2827db81e256b720